ArticleTranslational cancer research2025
Sublobar resection is non-inferior to lobectomy in octogenarians and older with stage Ia non‑small cell lung cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For individuals aged 80 years and older with early-stage non-small cell lung cancer (NSCLC), prior research has indicated that surgical intervention accompanied by lymphadenectomy may offer superior long-term survival outcomes compared to radiotherapy; however, the selection of the appropriate surgical approach continues to be a subject of debate. So, our aim is to compare overall survival (OS) differences between two surgical modalities (lobectomy and sublobar resection) in patients aged 80 years and older with pathological stage Ia NSCLC according to the 8th edition of the tumor-node-metastasis (TNM) staging system. Methods: Patients aged ≥80 years with pathological stage Ia (T1N0M0) NSCLC from 2004 to 2021 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. Patients were assigned to either the lobectomy or sublobar resection group. Optimal cutoff values for lymph nodes examined (LNE) were determined using X-Tile software, and lymph node status was classified into low dissection (1 to 5 lymph nodes) and high dissection (6 or more lymph nodes) groups. Confounding factors were controlled through propensity score matching (PSM) analysis, and OS results were analyzed using the Kaplan-Meier method. Survival-related factors were identified using multivariate Cox regression analysis. Results: A total of 1,735 patients were identified, with 30.0% in the sublobar resection group and 70.0% in the lobectomy group. The OS of the lobectomy group was significantly higher than that of the sublobar resection group (P=0.02). The 1-, 3-, and 5-year OS rates were 90.79%, 71.38%, and 56.60% for the sublobar resection group, respectively, compared to 89.87%, 76.88%, and 60.94% for the lobectomy group. In multivariate Cox regression analysis, the high lymph node dissection group demonstrated better prognosis [hazard ratio (HR) =0.796; 95% confidence interval (CI): 0.690-0.919; P=0.002]. Younger age, female sex, adenocarcinoma histology, and smaller tumor sizes were independent prognostic factors for improved OS. After PSM, no significant difference in OS was observed between the two groups (P=0.28), with 1-, 3-, and 5-year OS rates of 87.69%, 76.43%, and 56.41% in the lobectomy group, and 90.21%, 70.54%, and 55.65% in the sublobar resection group. Multivariate Cox regression indicated that the high lymph node dissection group had a better prognosis (HR =0.765; 95% CI: 0.620-0.944; P=0.01). Additionally, younger age and female sex were identified as independent prognostic factors for better OS. Conclusions: For patients aged 80 years and older diagnosed with stage Ia NSCLC, it is recommended that sublobar resection be performed in conjunction with the dissection of a minimum of six lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.